135637-46-6 Usage
Description
5-[4-methoxy-3-[(2S)-norbornan-2-yl]oxy-phenyl]-1,3-diazinan-2-one is a complex organic compound with a unique molecular structure. It is characterized by its diazinan-2-one core, which is substituted with a phenyl group at the 5th position. This phenyl group is further modified with a methoxy group and a norbornan-2-yloxy group, which are attached at the 4th and 3rd positions, respectively. The norbornan-2-yloxy group is in the (2S)-configuration, adding to the compound's stereochemical complexity. This molecule is of interest due to its potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
5-[4-methoxy-3-[(2S)-norbornan-2-yl]oxy-phenyl]-1,3-diazinan-2-one is used as a selective inhibitor of phosphodiesterase type 4 (PDE4) for the treatment of respiratory and neurological diseases. PDE4 isoforms play a crucial role in signal transduction by converting cyclic nucleotide second messengers cAMP and cGMP to 5'-AMP and 5'-GMP, respectively. By inhibiting PDE4, this compound can modulate cAMP levels, potentially leading to therapeutic benefits in conditions such as asthma, chronic obstructive pulmonary disease (COPD), and certain neurological disorders.
Used in Research Applications:
In addition to its potential therapeutic applications, 5-[4-methoxy-3-[(2S)-norbornan-2-yl]oxy-phenyl]-1,3-diazinan-2-one may also be used as a research tool to study the role of PDE4 in various biological processes. As a selective inhibitor, it can help researchers understand the specific functions of PDE4 isoforms and their contribution to disease pathology. This knowledge can be valuable in the development of targeted therapies and the identification of new drug targets.
Used in Drug Development:
The compound's ability to selectively inhibit PDE4 makes it a promising candidate for further drug development. Researchers can explore its potential in the creation of new medications for the treatment of respiratory and neurological diseases. Additionally, its unique molecular structure may serve as a starting point for the design of novel PDE4 inhibitors with improved potency, selectivity, and pharmacokinetic properties.
Biological Activity
Selective inhibitor of phosphodiesterase type 4 (IC 50 values are 1.9, > 100, > 100, > 100 and > 100 μ M for human lung PDE4, lung PDE1, lung PDE2, heart PDE3 and platelet PDE-V respectively) that displays no significant PDE4 isozyme selectivity. Inhibits hydrolysis of cAMP in isolated human peripheral blood monocytes, eosinophils and T cells.? Displays anti-inflammatory and bronchodilatory effects in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 135637-46-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,6,3 and 7 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 135637-46:
(8*1)+(7*3)+(6*5)+(5*6)+(4*3)+(3*7)+(2*4)+(1*6)=136
136 % 10 = 6
So 135637-46-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H24N2O3/c1-22-15-5-4-12(14-9-19-18(21)20-10-14)8-17(15)23-16-7-11-2-3-13(16)6-11/h4-5,8,11,13-14,16H,2-3,6-7,9-10H2,1H3,(H2,19,20,21)/t11-,13+,16+/m1/s1
135637-46-6Relevant articles and documents
Processes and intermediates in the synthesis of 5-(3-exo-bicyclo[2.2.1]hept-2-yloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one
-
Page column 19, (2008/06/13)
This invention relates to novel processes for preparing the pharmaceutically active compound 5-(3-[(2S)-exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one and its corresponding 2R enantiomer and for preparing certain in
